Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY2253651 nasal spray in obstructive sleep apnea
2017-001851-29Phase 2Terminated
- Sponsor
- Bayer
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BAY2253651 in obstructive sleep apnea hypopnea syndrome (OSAHS) (3 arms), sponsored by Bayer. Primary endpoint: Responder rate based on apnea-hypopnea index reduction. Started Aug 2018; status: terminated.
02
Drugs
BAY2253651
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2017-001851-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001851-29.